Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Hepatic steatosis assessment: a comparative study between surgeon evaluation and forward histopathologic findings.

Martins AM, Coelho GR, Marques GA, Moraes MO, Valença Jr JT, Garcia JH.

Arq Gastroenterol. 2013 Jan-Mar;50(1):15-8.

2.

Use of severely steatotic grafts in liver transplantation: a matched case-control study.

McCormack L, Petrowsky H, Jochum W, Mullhaupt B, Weber M, Clavien PA.

Ann Surg. 2007 Dec;246(6):940-6; discussion 946-8.

PMID:
18043095
3.

Assessment of hepatic steatosis by transplant surgeon and expert pathologist: a prospective, double-blind evaluation of 201 donor livers.

Yersiz H, Lee C, Kaldas FM, Hong JC, Rana A, Schnickel GT, Wertheim JA, Zarrinpar A, Agopian VG, Gornbein J, Naini BV, Lassman CR, Busuttil RW, Petrowsky H.

Liver Transpl. 2013 Apr;19(4):437-49. doi: 10.1002/lt.23615. Epub 2013 Mar 17.

4.

The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment.

Spitzer AL, Lao OB, Dick AA, Bakthavatsalam R, Halldorson JB, Yeh MM, Upton MP, Reyes JD, Perkins JD.

Liver Transpl. 2010 Jul;16(7):874-84. doi: 10.1002/lt.22085.

5.

Testing liver allocation in São Paulo, Brazil: the relationship of model for end-stage liver disease implementation with a reduction in waiting-list mortality.

Salvalaggio PR, Afonso RC, Pereira LA, Ferraz-Neto BH.

Transplant Proc. 2012 Oct;44(8):2283-5. doi: 10.1016/j.transproceed.2012.07.045.

PMID:
23026574
6.

Frozen-section diagnosis in donor livers: error rate estimation of steatosis degree.

D'Alessandro E, Calabrese F, Gringeri E, Valente M.

Transplant Proc. 2010 Jul-Aug;42(6):2226-8. doi: 10.1016/j.transproceed.2010.05.033.

PMID:
20692450
7.

Liver transplantation in patients with cystic fibrosis: analysis of United Network for Organ Sharing data.

Mendizabal M, Reddy KR, Cassuto J, Olthoff KM, Faust TW, Makar GA, Rand EB, Shaked A, Abt PL.

Liver Transpl. 2011 Mar;17(3):243-50. doi: 10.1002/lt.22240.

8.

Liver grafts procured by other transplant teams do not affect posttransplantation outcomes.

Salvalaggio PR, Ferraz-Neto BH.

Transplant Proc. 2012 Oct;44(8):2293-6. doi: 10.1016/j.transproceed.2012.07.043.

PMID:
23026577
9.

Multicentric evaluation of model for end-stage liver disease-based allocation and survival after liver transplantation in Germany--limitations of the 'sickest first'-concept.

Weismüller TJ, Fikatas P, Schmidt J, Barreiros AP, Otto G, Beckebaum S, Paul A, Scherer MN, Schmidt HH, Schlitt HJ, Neuhaus P, Klempnauer J, Pratschke J, Manns MP, Strassburg CP.

Transpl Int. 2011 Jan;24(1):91-9. doi: 10.1111/j.1432-2277.2010.01161.x. Epub 2010 Sep 3.

10.

The impact of the model for end-stage liver disease (MELD) on liver transplantation in one center in Brazil.

Freitas AC, Itikawa WM, Kurogi AS, Stadnik LG, Parolin MB, Coelho JC.

Arq Gastroenterol. 2010 Jul-Sep;47(3):233-7.

11.

Discarded organs at Shiraz Transplant Center.

Shamsaeefar A, Nikeghbalian S, Kazemi K, Mansorian M, Gholami S, Motazedian N, Malekhosseini SA.

Exp Clin Transplant. 2014 Mar;12 Suppl 1:178-81.

12.

Use of steatotic graft in living-donor liver transplantation.

Soejima Y, Shimada M, Suehiro T, Kishikawa K, Yoshizumi T, Hashimoto K, Minagawa R, Hiroshige S, Terashi T, Ninomiya M, Shiotani S, Harada N, Sugimachi K.

Transplantation. 2003 Jul 27;76(2):344-8.

PMID:
12883190
13.

Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation.

Manousou P, Dhillon AP, Isgro G, Calvaruso V, Luong TV, Tsochatzis E, Xirouchakis E, Kalambokis G, Cross TJ, Rolando N, O'Beirne J, Patch D, Thornburn D, Burroughs AK.

Liver Transpl. 2011 Feb;17(2):178-88. doi: 10.1002/lt.22209.

14.

Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors.

Tran TT, Changsri C, Shackleton CR, Poordad FF, Nissen NN, Colquhoun S, Geller SA, Vierling JM, Martin P.

J Gastroenterol Hepatol. 2006 Feb;21(2):381-3.

PMID:
16509862
15.

Hepatic steatosis in liver transplant donors: common feature of donor population?

Garcia Ureña MA, Colina Ruiz-Delgado F, Moreno González E, Jiménez Romero C, García García I, Loinzaz Segurola C, Gonzalez-Pinto, Gómez Sanz R.

World J Surg. 1998 Aug;22(8):837-44.

PMID:
9673556
16.

Impact of MELD allocation policy on survival outcomes after liver transplantation: a single-center study in northeast Brazil.

Batista TP, Sabat BD, Melo PS, Miranda LE, Fonseca-Neto OC, Amorim AG, Lacerda CM.

Clinics (Sao Paulo). 2011;66(1):57-64.

17.

Model for end-stage liver disease and model for end-stage liver disease-Na scores predict both before-listing and wait-list mortality.

Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Nojiri K, Aoki T, Sakamoto Y, Hasegawa K, Koike K, Kokudo N.

Transplant Proc. 2012 Mar;44(2):389-92. doi: 10.1016/j.transproceed.2012.01.037.

PMID:
22410024
18.

Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection.

Shi JP, Fan JG, Wu R, Gao XQ, Zhang L, Wang H, Farrell GC.

J Gastroenterol Hepatol. 2008 Sep;23(9):1419-25. doi: 10.1111/j.1440-1746.2008.05531.x.

PMID:
18853998
19.

Is Model for End-Stage Liver Disease score associated with quality of life after liver transplantation?

Rodrigue JR, Nelson DR, Reed AI, Hanto DW, Curry MP.

Prog Transplant. 2011 Sep;21(3):207-14.

PMID:
21977881
20.

Expanding the donor pool for liver transplantation in the setting of an "opt-out" scheme: 3 years after new legislation.

Lee VT, Yip CC, Ganpathi IS, Chang S, Mak KS, Prabhakaran K, Madhavan K.

Ann Acad Med Singapore. 2009 Apr;38(4):315-7.

Supplemental Content

Support Center